Corporate Misconduct Accountability Project
CJH, Inc. d/b/a Ginesis Natural Products · EPA Administrative Enforcement Action – Consent Agreement
Ginesis Sold Fake COVID Disinfectant, EPA Says. Penalty: $45,000
Alabama company marketed unregistered pesticide as ‘effective against Corona’ during pandemic without EPA approval, potentially endangering consumers who relied on unverified health claims.
HIGH SEVERITY
TL;DR
During the COVID-19 pandemic, Ginesis Natural Products sold a disinfectant spray claiming it was ‘effective against Corona’ and ‘inactivates viruses and bacteria’ without EPA registration or scientific verification. The company also sold a lice repellent spray without proper labeling for years. EPA found both products violated federal pesticide law designed to protect public health. The company settled for $45,000 without admitting wrongdoing.
This case shows how companies can exploit regulatory exemptions during public health crises, leaving consumers vulnerable to unproven products when they need protection most.
$45,000
Total civil penalty for years of violations
2 products
Unregistered pesticides sold to public
4+ years
Period of alleged non-compliance
The Allegations: A Breakdown
Core Allegations
What they did · 8 points
| 01 | Ginesis sold ‘Ginesis Antimicrobial’ spray from August 2020 through December 2022 and beyond, making explicit claims it ‘inactivates viruses and bacteria’ and was ‘Safe formulation is effective against Corona’ without EPA registration. The company marketed this product during the pandemic when consumers desperately sought protection against COVID-19. | high |
| 02 | The company falsely claimed its antimicrobial product qualified as a ‘minimum risk pesticide’ exempt from registration. EPA found this claim invalid because products claiming to control microorganisms that pose threats to human health cannot use this exemption under federal law. | high |
| 03 | Ginesis sold ‘Nit Free Mint Repelling Lice Spray’ from April 2019 through July 2021 with pesticidal claims like ‘Designed to repel lice using natural peppermint oil’ without proper registration. The product label failed to display the name and percentage of each active ingredient, violating basic safety disclosure requirements. | medium |
| 04 | The company displayed its website URL on product labels, making the website legally part of the product labeling. This website contained the unverified health claims about coronavirus effectiveness, spreading potentially misleading information to consumers researching the products. | high |
| 05 | EPA inspectors found both unregistered products being held for sale at the Alabama facility in April 2023. Sales records documented multiple transactions over years, showing this was not an isolated incident but a sustained pattern of selling unregistered pesticides. | high |
| 06 | Federal law requires pesticides sold in the United States to be registered with EPA to ensure safety and effectiveness. Ginesis bypassed this entire scientific review process, bringing products to market without independent verification that they worked as claimed or could be used safely. | high |
| 07 | The antimicrobial product label provided specific treatment instructions, telling consumers to let the product stand for 10 minutes to treat bacteria on hard surfaces and 30 seconds for sanitizing. These detailed usage claims required EPA registration and scientific substantiation, which the product lacked. | medium |
| 08 | The company settled the case for $45,000 without admitting to the specific factual allegations. This ‘neither admit nor deny’ settlement allowed Ginesis to resolve years of alleged violations without formally acknowledging it sold unregistered pesticides with unverified pandemic protection claims. | medium |
Regulatory Failures
How oversight broke down · 6 points
| 01 | EPA did not discover the violations until March 2023, despite the antimicrobial product being sold since August 2020 and the lice spray since April 2019. The agency’s website review and facility inspection came years after these unregistered products entered the market. | medium |
| 02 | The minimum risk pesticide exemption created a pathway companies could exploit. Ginesis claimed this exemption while making explicit human health claims about viruses and bacteria, showing how regulatory categories can be misapplied when companies self-certify compliance. | high |
| 03 | Federal regulations specifically prohibit minimum risk pesticides from claiming to control microorganisms that pose threats to human health, including disease-transmitting bacteria or viruses. Ginesis’s ‘effective against Corona’ claim directly violated this prohibition, yet the product remained on the market for years. | high |
| 04 | The settlement process allowed Ginesis to avoid formal adjudication of the facts. The consent agreement resolved the matter administratively without a hearing or trial, meaning the company never had to publicly defend its actions in a formal proceeding. | medium |
| 05 | EPA’s enforcement relied on post-market detection through website monitoring and physical inspections. The system provided no mechanism to prevent unregistered products from reaching consumers in the first place, placing the burden of risk on the public. | high |
| 06 | The penalty amount must be weighed against years of product sales. The consent agreement provided no transparency about the company’s revenue from these products or whether the $45,000 fine exceeded, matched, or fell short of the profits generated from non-compliance. | medium |
Profit Over People
The business calculation · 6 points
| 01 | Ginesis brought its antimicrobial product to market in August 2020, just months into the COVID-19 pandemic. The timing suggests the company moved quickly to capitalize on public fear and demand for disinfectant products, bypassing the time and expense of EPA registration. | high |
| 02 | Full EPA registration requires testing, data submission, and lengthy scientific review, creating costs and delays. Ginesis avoided this entire process while still making powerful product claims, gaining a competitive advantage over companies that followed the rules. | high |
| 03 | The company sold both products for multiple years through its website using add-to-cart features, building sustained revenue streams. Sales records showed transactions spanning from April 2019 through December 2022, demonstrating this was a core part of the business model, not an oversight. | high |
| 04 | Marketing claims included ‘Safe formulation is effective against Corona’ and instructions for treating bacteria, creating strong consumer appeal during a public health crisis. These specific, actionable claims likely drove sales among consumers seeking protection, despite lacking EPA verification. | high |
| 05 | The $45,000 settlement may have cost less than proper EPA registration and ongoing compliance would have. If companies view penalties as merely a cost of doing business rather than a true deterrent, the incentive structure favors pushing regulatory boundaries in pursuit of profit. | high |
| 06 | Ginesis operated from a facility in Waterloo, Alabama, holding products for sale and distribution when EPA inspected in April 2023. The physical inventory and distribution infrastructure showed an established operation, not a small-scale seller unaware of regulatory requirements. | medium |
Public Health and Safety
Who paid the price · 7 points
| 01 | Consumers relying on claims that Ginesis Antimicrobial was ‘effective against Corona’ may have used an unverified product for protection against a deadly virus. This false sense of security could have led to inadequate disinfection and increased health risks during the pandemic. | high |
| 02 | EPA registration exists to verify that pesticides are effective against claimed targets and can be used without unreasonable adverse effects on human health. Ginesis customers received no such assurance because the products never underwent this scientific review. | high |
| 03 | The lice repellent spray failed to list active ingredient names and percentages on its label. This omission denied consumers crucial information about what they were applying to their children’s heads, preventing informed decisions about potential allergies or sensitivities. | medium |
| 04 | Federal regulations explicitly bar minimum risk pesticides from claiming to control microorganisms posing threats to human health. Ginesis violated this safeguard designed specifically to prevent companies from making unverified disease prevention claims to vulnerable consumers. | high |
| 05 | If the antimicrobial product was ineffective despite its claims, users may have been exposed to pathogens they believed they had eliminated. This gap between marketed protection and actual performance creates direct health risks, especially for immunocompromised individuals. | high |
| 06 | If the lice spray did not work as claimed, families could have continued suffering from infestations, leading to further spread in schools and communities. Ineffective treatments can also drive use of harsher chemical alternatives, creating additional health exposures. | medium |
| 07 | The consent agreement acknowledged the company is currently in compliance and violations have been corrected. However, consumers who purchased these products between 2019 and 2023 received no compensation or notification about the unregistered status of what they bought. | medium |
Corporate Accountability Failures
How they avoided responsibility · 8 points
| 01 | The consent agreement explicitly states Ginesis ‘neither admits nor denies the specific factual allegations’ in the case. The company paid $45,000 but never formally acknowledged selling unregistered pesticides or making unverified coronavirus protection claims. | high |
| 02 | No admission of facts means no official finding that Ginesis marketed a product as ‘effective against Corona’ without scientific backing during a pandemic. This legal outcome obscures the severity of potentially misleading consumers about virus protection when they needed it most. | high |
| 03 | The settlement includes no transparency requirement about product revenues or profits. The public cannot assess whether the $45,000 penalty provided meaningful deterrence or merely represented a small fraction of the income generated from years of non-compliant sales. | medium |
| 04 | Settling without admission makes it harder for harmed individuals to seek recourse. Without official adjudication of the facts, consumers who bought these products based on unverified claims have no legal foundation established for potential civil actions. | medium |
| 05 | The consent agreement was filed May 13, 2025, becoming effective immediately. This quick administrative resolution avoided any public hearing or trial where evidence would be presented, witnesses examined, and facts established through adversarial process. | medium |
| 06 | Ginesis certified it is currently in compliance with all FIFRA requirements and has corrected the violations. This forward-looking commitment creates no accountability for past harm and provides no remedy for consumers who relied on the unregistered products. | medium |
| 07 | The agreement bars Ginesis from claiming the settlement is admission of liability or violation. This protective language insulates the company’s reputation while denying the public a clear acknowledgment that federal pesticide laws were broken for years. | high |
| 08 | EPA reserved the right to pursue criminal sanctions and injunctive relief for any violations of law. However, the agency chose administrative settlement over more aggressive enforcement, accepting a financial penalty as sufficient resolution for alleged pandemic-era misconduct. | medium |
Exploiting Delay
Years of violations before action · 6 points
| 01 | Ginesis sold the lice spray from April 2019 through at least July 2021 before EPA took action. The company operated for over two years selling a pesticide with improper labeling before regulators intervened, allowing sustained market presence for a non-compliant product. | medium |
| 02 | The antimicrobial product entered the market in August 2020 and remained on sale through December 2022 according to sales records. EPA did not conduct its website review until March 2023 and facility inspection until April 2023, meaning the unregistered disinfectant sold for over two years. | high |
| 03 | The product was still being offered for sale on the company website when EPA reviewed it in March 2023, over two years after initial sales began. This extended availability shows the company continued marketing unregistered pesticides even as the pandemic evolved and public awareness grew. | medium |
| 04 | From initial website review in March 2023 to the consent agreement filing in May 2025, over two years elapsed. This enforcement timeline meant Ginesis resolved the matter through negotiated settlement rather than facing immediate consequences or injunctive orders to stop sales. | medium |
| 05 | EPA’s enforcement approach relied on detection after products reached the market rather than preventing their sale. This reactive model allowed unregistered pesticides with pandemic health claims to be purchased by consumers before any regulatory intervention occurred. | high |
| 06 | The consent agreement process itself took two years from inspection to final order. During this period, the company could negotiate terms, prepare its defense, and manage the situation, while consumers who bought the products years earlier received no notification or remedy. | medium |
The Bottom Line
What this case reveals · 6 points
| 01 | Ginesis Natural Products allegedly exploited a public health crisis to market unregistered pesticides making unverified coronavirus protection claims. The company settled for $45,000 without admitting facts, avoiding accountability for potentially endangering consumers who relied on these products for pandemic protection. | high |
| 02 | The case exposes how regulatory exemptions designed for low-risk products can be misapplied by companies seeking to avoid costly registration requirements. Self-certification systems place initial compliance burden on companies rather than requiring pre-market government approval for health-protective products. | high |
| 03 | Financial settlements without admission of wrongdoing may fail to provide meaningful deterrence. If $45,000 represents a manageable cost compared to years of product revenue, other companies might view similar violations as acceptable business risks with limited reputational consequences. | high |
| 04 | Consumers who purchased these products between 2019 and 2023 received no compensation, notification, or acknowledgment of harm. The enforcement action resulted in a government penalty but provided no remedy for individuals who may have relied on unverified health claims during a deadly pandemic. | high |
| 05 | The multi-year gap between violations and enforcement demonstrates resource constraints in regulatory oversight. EPA’s reactive approach meant unregistered pesticides with explicit virus-control claims remained available for purchase throughout much of the COVID-19 pandemic without intervention. | high |
| 06 | This case illustrates tensions between expedient administrative settlements and robust public accountability. While EPA secured compliance and a penalty efficiently, the public lacks a formal finding of facts about what Ginesis did, creating questions about whether justice was truly served. | medium |
Timeline of Events
April 2019
Ginesis begins selling Nit Free Mint Repelling Lice Spray without proper EPA registration or labeling, according to sales records reviewed by EPA inspectors.
August 2020
Ginesis begins selling Ginesis Antimicrobial spray with claims it ‘inactivates viruses and bacteria’ and is ‘effective against Corona’ without EPA registration, just months into the COVID-19 pandemic.
July 2021
Last documented sale of Nit Free Mint Repelling Lice Spray according to sales records collected during EPA inspection, representing over two years of distribution.
December 2022
Last documented sale of Ginesis Antimicrobial according to sales records collected during EPA inspection, representing over two years of distribution during the pandemic.
March 27, 2023
EPA reviews Ginesis website and identifies unregistered pesticides being offered for sale with add-to-cart features. Website displays labels and claims for both products, including coronavirus effectiveness claims.
April 28, 2023
EPA authorized representative conducts inspection at Ginesis facility in Waterloo, Alabama. Inspector observes both products held for sale, collects labels and sales records documenting years of transactions.
May 13, 2025
Consent Agreement and Final Order filed. CJH, Inc. d/b/a Ginesis Natural Products settles for $45,000 civil penalty without admitting to specific factual allegations or violations.
Direct Quotes from the Legal Record
QUOTE 1
Unverified coronavirus protection claim
allegations
“Safe formulation is effective against Corona”
💡 Company marketed product as COVID protection during pandemic without any EPA verification of this claim
QUOTE 2
Explicit virus and bacteria claims
allegations
“Inactivates viruses and bacteria”
💡 This claim on product label disqualified it from minimum risk exemption and required full EPA registration
QUOTE 3
Detailed treatment instructions without approval
allegations
“To treat bacteria on hard surfaces let stand for 10 minutes”
💡 Product provided specific usage instructions for bacteria control without EPA registration or scientific validation
QUOTE 4
Sanitization claims requiring registration
allegations
“To sanitize: let stand for 30 seconds and then allow to air dry”
💡 Sanitization claims are pesticidal and require EPA approval, which this product lacked
QUOTE 5
Website considered part of labeling
regulatory
“Because the website URL was displayed on the labels for the Ginesis Antimicrobial and Nit Free Mint Repelling Lice Spray products, the website is considered to be a form of labeling for those pesticidal products”
💡 EPA determined website claims were legally part of product labeling, making online marketing subject to FIFRA requirements
QUOTE 6
Human health claims prohibited from exemption
regulatory
“for a product to be exempted under this section, the pesticide product must not bear claims either to control or mitigate microorganisms that pose a threat to human health, including but not limited to disease transmitting bacteria or viruses”
💡 Federal regulation explicitly bars the minimum risk exemption Ginesis claimed for products making these exact types of claims
QUOTE 7
Labeling requirement violation
allegations
“for a product to be exempt under Section 152.25(f), the pesticide product label must display the name and percentage (by weight) of each active ingredient”
💡 Lice spray failed this basic disclosure requirement, denying consumers information about what they were using
QUOTE 8
Years of documented sales
profit
“The sales records collected during the inspection showed that Respondent sold and distributed the Ginesis Antimicrobial product on one or more occasions between August 17, 2020, and December 12, 2022”
💡 EPA documented over two years of sustained sales during the pandemic, showing systematic rather than isolated violations
QUOTE 9
No admission of wrongdoing in settlement
accountability
“neither admits nor denies the specific factual allegations set forth in Section IV (Findings of Facts) of this CAFO”
💡 Company avoided admitting it sold unregistered pesticides with unverified pandemic protection claims
QUOTE 10
Certification of current compliance only
accountability
“certifies to the best of its knowledge that Respondent is currently in compliance with all relevant requirements of FIFRA and its implementing regulations, and that all violations alleged herein, which are neither admitted nor denied, have been corrected”
💡 Settlement focused on future compliance rather than accountability for past conduct or remedy for affected consumers
QUOTE 11
Federal registration requirement
regulatory
“it is unlawful for any person to distribute or sell to any person any pesticide that is not registered under Section 3 of FIFRA”
💡 Federal law makes unregistered pesticide sales illegal, yet Ginesis sold products for years without registration
QUOTE 12
Pesticide defined by intent
regulatory
“The person who distributes or sells the substance claims, states, or implies (by labeling or otherwise): That the substance (either by itself or in combination with any other substance) can or should be used as a pesticide”
💡 Federal regulations make clear that marketing claims determine whether a product is a pesticide requiring registration
QUOTE 13
Product still available during EPA review
delay_tactics
“Additionally, the product was being offered for sale on Respondent’s website at the time of the EPA’s website review on March 27, 2023”
💡 Ginesis continued offering unregistered antimicrobial online over two years after sales began, showing ongoing violations
QUOTE 14
Lice repellent claims
allegations
“Designed to repel lice using natural peppermint oil”
💡 Clear pesticidal claim that brought product under FIFRA requirements for registration and labeling
QUOTE 15
Settlement resolves civil penalties only
accountability
“Respondent’s full compliance with this CAFO shall only resolve Respondent’s liability for federal civil penalties for the violations and facts specifically alleged in Sections IV and V above”
💡 Settlement limited to this case, preserving EPA’s ability to pursue other violations but providing no consumer remedy
Frequently Asked Questions
What did Ginesis Natural Products do wrong?
Ginesis sold two pesticide products without EPA registration for years. The company marketed Ginesis Antimicrobial spray claiming it was ‘effective against Corona’ and ‘inactivates viruses and bacteria’ during the COVID-19 pandemic without any scientific verification. It also sold a lice repellent spray without proper ingredient labeling. Federal law requires pesticides to be registered with EPA before sale to ensure they are safe and effective.
Did Ginesis admit to these violations?
No. The consent agreement states Ginesis ‘neither admits nor denies’ the specific factual allegations. The company paid a $45,000 penalty and agreed to comply with federal pesticide law going forward, but never formally acknowledged selling unregistered pesticides or making unverified coronavirus protection claims.
How long did Ginesis sell these unregistered products?
Sales records showed Ginesis sold the lice spray from at least April 2019 through July 2021, and the antimicrobial spray from at least August 2020 through December 2022. The antimicrobial product was still being offered on the company website when EPA reviewed it in March 2023. This represents years of sustained sales before regulatory action.
Why is selling unregistered pesticides dangerous?
EPA registration involves scientific review to verify pesticides are effective against claimed targets and can be used without unreasonable harm to human health or the environment. Unregistered products bypass this safety evaluation entirely. Consumers using Ginesis’s antimicrobial product may have relied on unverified claims about coronavirus protection during a deadly pandemic, creating potential false security.
What is the minimum risk pesticide exemption Ginesis claimed?
Federal regulations exempt certain low-risk pesticides from full registration if they meet strict criteria about ingredients and labeling. However, products claiming to control microorganisms that pose threats to human health, like disease-causing viruses or bacteria, cannot use this exemption. Ginesis claimed the exemption for its antimicrobial product while explicitly marketing it as effective against coronavirus and bacteria.
Is $45,000 an adequate penalty for these violations?
The consent agreement provides no information about how much revenue Ginesis generated from selling these products over multiple years. Without transparency about profits, the public cannot assess whether the penalty provided meaningful deterrence or merely represented a small cost of doing business. The company also avoided admitting wrongdoing, limiting reputational consequences.
Will consumers who bought these products get refunds?
The consent agreement contains no provisions for consumer compensation or notification. The settlement resolved EPA’s enforcement action against the company but did not create any remedy for individuals who purchased the products based on unverified health claims between 2019 and 2023.
Why did it take EPA years to take action?
EPA did not review the Ginesis website until March 2023 and did not inspect the facility until April 2023, years after both products entered the market. The agency’s enforcement approach is reactive, relying on post-market detection rather than preventing unregistered products from reaching consumers. The consent agreement was not filed until May 2025, over two years after the inspection.
Are these products still being sold?
The consent agreement states Ginesis certified it is currently in compliance with federal pesticide law and has corrected the violations. This suggests the company either registered the products properly or stopped selling them with the pesticidal claims. However, the agreement requires no public disclosure about the products’ current status.
What can I do if I bought one of these products?
You can file a complaint with EPA Region 4 if you experienced harm or believe you were misled. You might also consult a consumer protection attorney about potential civil claims, though the lack of admitted facts in the settlement may complicate such cases. Going forward, verify that pesticide products making health protection claims display an EPA registration number on their labels.
You can read about this case on the EPA’s website by visiting this following link: https://yosemite.epa.gov/oa/rhc/epaadmin.nsf/Filings/91F00D41F671567285258C89006DB1ED/$File/CJH%20Inc%20dba%20Ginesis%20Natural%20Products%20CAFO%205-13-25%20FIFRA-04-2024-3020(b).pdf
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
